Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells.
about
The Future of Smallpox Vaccination: is MVA the key?Susceptibility of different leukocyte cell types to Vaccinia virus infectionPoxvirus vectors as HIV/AIDS vaccines in humansPrime-boost approaches to tuberculosis vaccine developmentMatrix and backstage: cellular substrates for viral vaccinesPoxvirus tropismPrinciples of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agentsGene Expression Driven by a Strong Viral Promoter in MVA Increases Vaccination Efficiency by Enhancing Antibody Responses and Unmasking CD8⁺ T Cell EpitopesPre-clinical efficacy and safety of experimental vaccines based on non-replicating vaccinia vectors against yellow feverModified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseasesCapturing of cell culture-derived modified Vaccinia Ankara virus by ion exchange and pseudo-affinity membrane adsorbers.Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection.Experimental vaccines against potentially pandemic and highly pathogenic avian influenza virusesOriginal encounter with antigen determines antigen-presenting cell imprinting of the quality of the immune response in mice.Replication of modified vaccinia virus Ankara in primary chicken embryo fibroblasts requires expression of the interferon resistance gene E3L.Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategiesModified vaccinia virus Ankara exerts potent immune modulatory activities in a murine modelFeline calicivirus capsid protein expression and capsid assembly in cultured feline cells.Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes miceHuman parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy.Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region.Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus.Phase II randomized, double-blinded comparison of a single high dose (5×10(8) TCID50) of modified vaccinia Ankara compared to a standard dose (1×10(8) TCID50) in healthy vaccinia-naïve individuals.Comparative analysis of MVA-CD40L and MVA-TRICOM vectors for enhancing the immunogenicity of chronic lymphocytic leukemia (CLL) cells.In vitro host range, multiplication and virion forms of recombinant viruses obtained from co-infection in vitro with a vaccinia-vectored influenza vaccine and a naturally occurring cowpox virus isolate.Immediate-early expression of a recombinant antigen by modified vaccinia virus ankara breaks the immunodominance of strong vector-specific B8R antigen in acute and memory CD8 T-cell responsesIntroduction of the six major genomic deletions of modified vaccinia virus Ankara (MVA) into the parental vaccinia virus is not sufficient to reproduce an MVA-like phenotype in cell culture and in mice.Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus AnkaraImmune interventions in HIV infection.Escape in one of two cytotoxic T-lymphocyte epitopes bound by a high-frequency major histocompatibility complex class I molecule, Mamu-A*02: a paradigm for virus evolution and persistence?Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration.Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene.Smallpox vaccines: targets of protective immunity.A novel naturally occurring tandem promoter in modified vaccinia virus ankara drives very early gene expression and potent immune responsesExpression of CCL20 and granulocyte-macrophage colony-stimulating factor, but not Flt3-L, from modified vaccinia virus ankara enhances antiviral cellular and humoral immune responses.Modified vaccinia virus Ankara-infected dendritic cells present CD4+ T-cell epitopes by endogenous major histocompatibility complex class II presentation pathwaysA prime/boost strategy using DNA/fowlpox recombinants expressing the genetically attenuated E6 protein as a putative vaccine against HPV-16-associated cancers.The vaccinia virus O1 protein is required for sustained activation of extracellular signal-regulated kinase 1/2 and promotes viral virulence.Percutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored Vaccines
P2860
Q24801195-5520AC70-66F1-4FD8-BD05-580244650E5CQ24801903-D200DE4A-21D5-4D21-B182-B09270E1A547Q26995078-405D3B84-2130-4C69-A3BE-A24D2EA011B4Q27024526-D413444E-2D80-4DE7-846A-2B73FA208A80Q27025941-204F14E9-18E0-406A-8D09-2948C20F7220Q28237434-81BEE08F-98AC-4D43-BB01-031AEA06A8D1Q28384852-081E50BA-FCBE-416F-AEE2-6010533C29ABQ28647428-20806F46-9FF7-4A7B-BBAB-B12661487258Q28740522-14E9778C-177A-4EA6-B84A-0EC846DD71D7Q30209342-AA01C62E-8329-4A4F-939F-1D2983CDB39AQ30227439-FCB4BB8F-4A0D-4603-AE14-66646CDCC984Q30375489-61165F3D-026C-4870-B5E5-234C9082B768Q30427591-7824D111-D232-41EB-9347-F8837A69B120Q30973875-EDA2E4E3-EA1B-4E42-89F6-1D1CE6B52625Q33187731-BB14583A-A824-4658-8C86-45D2B75CDBD2Q33320536-0A86C2F5-C966-48A3-A4D5-4399B06BC4D2Q33440600-F2DAEDD6-6D08-4FF2-8366-BE30CF2B0FD4Q33632203-7607ADFD-4F18-4979-A094-FB4154931680Q33639951-E964CAD3-D060-4340-9E2E-10D96FD1EEB2Q33696283-EC7BC56A-F17A-412F-89D1-37075FD17D24Q33808578-3CB9ED08-962B-4BB2-987C-AF0109A79E6DQ33834543-A01A374E-2510-496D-A551-FF469B6012BAQ33843163-E5D36765-13D5-442C-8293-EE1C98E2089AQ33930815-170CC903-56B3-441E-B4FB-FB512C8E1442Q33938820-2F54098E-89BC-4938-B72E-97E70CB1332CQ34017475-8256E1E1-A08D-4062-A30C-457C8F4522B2Q34055541-D587D920-63EF-4637-84A7-3AAADD566C9AQ34120696-3CDE1619-8240-4916-BBAF-E471237D90B3Q34343169-D1529BFA-FBDA-4DFD-A208-69BD2677608DQ34351326-4ADBE128-23CE-46C9-ADA0-DCEE2B754F47Q34356817-E1F4794F-2912-47DE-8BFC-03FC994C33D8Q34470311-F97115CE-AA63-4669-9C4B-5FF066BB3CC2Q34651266-1DBB7F31-761E-47C2-AA8F-A8BAB2F42B20Q34780607-EFDDB17A-8EE3-42F2-B61F-67FD73D4F2F0Q34952043-3411A35A-4850-4725-9007-7A7B8A0D733DQ35023778-FBA3A4BF-9360-4BC3-8FB9-96B76AD5B497Q35076771-EE317727-C0D2-43DE-BB50-19821A6E3965Q35154570-97B6F971-A536-423C-BECF-7B6DA420B5ADQ35826480-0724DD08-FD78-41E2-A368-BA2F0AE2CB2FQ35928588-490361F2-2927-4998-A90F-D31BB1C919D4
P2860
Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Highly attenuated modified vac ...... transformed and primary cells.
@en
type
label
Highly attenuated modified vac ...... transformed and primary cells.
@en
prefLabel
Highly attenuated modified vac ...... transformed and primary cells.
@en
P2093
P1476
Highly attenuated modified vac ...... transformed and primary cells.
@en
P2093
P304
P356
10.1099/0022-1317-79-2-347
P407
P478
79 ( Pt 2)
P50
P577
1998-02-01T00:00:00Z